Gallbladder issues after gastric sleeve surgery are among the most common post-operative complications, affecting a significant proportion of patients in the months following their procedure. Sleeve gastrectomy promotes rapid weight loss, which alters bile composition and reduces gallbladder motility — both key drivers of gallstone formation. Understanding why these problems arise, how to recognise the symptoms, and what treatment and preventive options are available is essential for anyone who has undergone bariatric surgery. This article outlines the mechanisms, diagnosis, management, and long-term outlook, aligned with NHS and NICE guidance.

Why Gastric Sleeve Surgery Increases Gallstone Risk

Sleeve gastrectomy increases gallstone risk because rapid fat breakdown causes the liver to oversaturate bile with cholesterol, promoting crystallisation; reduced gallbladder motility from lower food intake further concentrates bile.

Sleeve gastrectomy, one of the most commonly performed bariatric procedures in the UK, involves removing approximately 75–80% of the stomach to create a narrow, sleeve-shaped pouch. Whilst this leads to significant and sustained weight loss, the rapid reduction in body weight that follows surgery substantially increases the risk of developing gallstones — a well-recognised complication in the bariatric literature.

The primary mechanism relates to changes in bile composition during rapid weight loss. When the body breaks down fat stores quickly, the liver secretes excess cholesterol into bile, making it supersaturated. This cholesterol-rich bile is prone to crystallisation, forming gallstones within the gallbladder. Studies suggest that up to 30–40% of patients undergoing bariatric surgery may develop gallstones within the first six to twelve months post-operatively if no preventive measures are taken; however, this figure refers to gallstone formation overall (including asymptomatic stones detected on imaging) and not solely to symptomatic disease requiring treatment. The proportion who develop symptoms or complications is lower. Risk is highest in the first six to twelve months, then declines as the rate of weight loss slows.

Additional contributing factors include:

• Reduced gallbladder motility: Decreased food intake means the gallbladder contracts less frequently, allowing bile to stagnate and concentrate.

• Altered gut hormones: Changes in cholecystokinin (CCK) secretion following sleeve gastrectomy may impair gallbladder emptying, though the evidence for this mechanism is not yet uniform and further research is ongoing.

• Pre-existing risk factors: Many patients presenting for bariatric surgery already carry risk factors for gallstone disease, including obesity, female sex, and metabolic syndrome.

Understanding these mechanisms is important for both patients and clinicians, as it informs the rationale for preventive treatment and the need for vigilant post-operative monitoring.

Common Gallbladder Symptoms Following Weight Loss Surgery

The most characteristic symptom is biliary colic — cramping upper right abdominal pain after eating, often with nausea — but fever, jaundice, or severe epigastric pain radiating to the back indicate potentially serious complications requiring urgent assessment.

Gallbladder problems after gastric sleeve surgery can present in a variety of ways, ranging from entirely asymptomatic gallstones — discovered incidentally on imaging — to acute, potentially serious complications requiring urgent intervention. Recognising the typical symptom pattern is essential for timely diagnosis and management.

The most characteristic symptom is biliary colic: a cramping or sharp pain in the upper right abdomen or epigastric region, often radiating to the right shoulder or back. This pain typically occurs after eating, particularly following fatty or rich meals, and may last from 30 minutes to several hours before resolving. Nausea and vomiting frequently accompany these episodes.

More concerning symptoms that may indicate complications include:

• Persistent or worsening abdominal pain that does not settle within a few hours

• Fever and chills, which may suggest acute cholecystitis (inflammation of the gallbladder) or cholangitis (infection of the bile ducts)

• Jaundice — yellowing of the skin or whites of the eyes — indicating possible bile duct obstruction by a migrated stone

• Dark urine and pale stools, further signs of biliary obstruction

• Severe, constant epigastric pain radiating to the back, accompanied by vomiting, which may indicate gallstone pancreatitis and requires urgent assessment

• Bloating, indigestion, and intolerance to fatty foods, which may be subtler, ongoing symptoms

It is worth noting that some post-sleeve patients may attribute symptoms such as nausea, bloating, or upper abdominal discomfort to their altered digestive anatomy rather than gallbladder disease. This can delay presentation. Any new or persistent upper abdominal symptoms following bariatric surgery should be assessed promptly by a healthcare professional.

Diagnosis and Assessment: What to Expect on the NHS

Diagnosis begins with clinical history, blood tests (LFTs, FBC, CRP, amylase), and abdominal ultrasound as first-line imaging per NICE CG188; MRCP is arranged if common bile duct involvement is suspected.

If gallbladder problems are suspected following sleeve gastrectomy, a structured diagnostic approach is followed, typically initiated by a GP or the bariatric follow-up team. Early and accurate diagnosis is important to distinguish uncomplicated gallstone disease from more serious biliary complications.

Initial assessment will usually include a thorough clinical history and physical examination. The GP or clinician will ask about the nature, timing, and triggers of symptoms, alongside a review of the patient's surgical history and current medications. Blood tests are commonly requested, including:

• Liver function tests (LFTs) — to detect biliary obstruction or hepatic involvement; the pattern of LFT abnormality (e.g., raised bilirubin and alkaline phosphatase) alongside clinical features helps assess the likelihood of common bile duct stones (choledocholithiasis) and guides decisions about further imaging or referral

• Full blood count (FBC) — to identify signs of infection or inflammation

• C-reactive protein (CRP) — as a marker of acute inflammation

• Amylase or lipase — if pancreatitis is a concern

Ultrasound of the abdomen is the first-line imaging investigation recommended by NICE and NHS guidelines for suspected gallstone disease (NICE CG188). It is non-invasive, widely available, and highly sensitive for detecting gallstones and gallbladder wall thickening. However, ultrasound is less reliable for visualising stones within the common bile duct.

If bile duct involvement is suspected, further imaging such as magnetic resonance cholangiopancreatography (MRCP) is typically arranged. In some centres, endoscopic ultrasound (EUS) may be used as an alternative when MRCP is unsuitable or the result is equivocal. In acute presentations, patients may be referred directly to a surgical assessment unit or accident and emergency department. NICE guidance (CG188) on gallstone disease provides a clear framework for investigation and onward referral, and NHS bariatric teams will often have dedicated pathways for post-operative complications to ensure timely specialist review.

Treatment Options for Gallbladder Problems After Sleeve Gastrectomy

Laparoscopic cholecystectomy is the definitive treatment for symptomatic gallstones, supported by NICE CG188; dietary modification, analgesia, and ERCP for duct stones are used as interim or adjunct measures.

The management of gallbladder problems following sleeve gastrectomy depends on the severity of symptoms, the presence of complications, and the patient's overall health status. Treatment ranges from conservative measures for mild, infrequent symptoms to surgical intervention for recurrent or complicated disease.

Laparoscopic cholecystectomy — keyhole surgical removal of the gallbladder — remains the definitive treatment for symptomatic gallstone disease and is the most commonly performed elective abdominal operation in the UK. For post-bariatric patients, this procedure is generally safe and effective, though the surgical team should be informed of the prior sleeve gastrectomy, as altered anatomy may influence operative planning. NICE guidance (CG188) supports cholecystectomy for patients with symptomatic gallstones, acute cholecystitis, or gallstone-related complications.

For patients who are not immediately fit for surgery, or whilst awaiting an operation, the following approaches may be considered:

• Dietary modification: Reducing fat intake can help minimise biliary colic episodes, as fatty meals are a primary trigger for gallbladder contraction.

• Analgesia: Non-steroidal anti-inflammatory drugs (NSAIDs) such as diclofenac are recommended by NICE (CG188) for acute biliary colic, with opioids reserved for more severe pain. However, patients who have undergone sleeve gastrectomy may be at increased risk of gastrointestinal side effects from NSAIDs; local bariatric protocols often advise caution, avoidance where possible, or co-prescription of a proton pump inhibitor (PPI). Patients should seek advice from their bariatric team or GP before taking NSAIDs. Any suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme (www.mhra.gov.uk/yellowcard or the Yellow Card app).

• Endoscopic retrograde cholangiopancreatography (ERCP): If a stone has migrated into the common bile duct (choledocholithiasis), ERCP may be performed to remove it, often prior to cholecystectomy.

In cases of acute cholecystitis, hospital admission, intravenous antibiotics, and early laparoscopic cholecystectomy are recommended. NICE CG188 advises offering surgery within one week of diagnosis; many centres aim to operate earlier where clinically feasible. Patients should be counselled that removal of the gallbladder does not impair digestion in the long term, as bile continues to flow directly from the liver into the small intestine. A small number of patients may experience loose stools or increased bowel frequency (bile acid diarrhoea) after cholecystectomy; this is usually manageable and can be discussed with a clinician if it occurs.

Preventive Measures and Ursodeoxycholic Acid Prescribing

Ursodeoxycholic acid (UDCA) 250–300 mg twice daily for approximately six months is the main pharmacological prophylaxis after bariatric surgery, used off-label to reduce bile cholesterol saturation and lower gallstone risk.

Given the well-established link between rapid post-operative weight loss and gallstone formation, prevention is a key component of post-bariatric care. Both pharmacological and lifestyle strategies play an important role in reducing the risk of gallbladder issues after gastric sleeve surgery.

Ursodeoxycholic acid (UDCA), a naturally occurring bile acid, is the principal pharmacological agent used for gallstone prophylaxis following bariatric surgery. It works by reducing the cholesterol saturation of bile, thereby inhibiting the crystallisation process that leads to stone formation. UDCA is a licensed medicine in the UK (MHRA-approved), with established indications including dissolution of cholesterol gallstones and primary biliary cholangitis (PBC). Its use as prophylaxis following bariatric surgery is an off-label application; prescribing in this context should follow local NHS and bariatric team protocols, and the decision should be made on an individual basis following discussion of the potential benefits and risks.

When prescribed for post-bariatric prophylaxis, UDCA is typically given at a dose of 250–300 mg twice daily (total 500–600 mg daily), taken orally, for approximately six months following surgery — the period of highest risk during rapid weight loss. Exact dosing and duration may vary between NHS trusts. Evidence from randomised controlled trials and meta-analyses suggests that UDCA can reduce the incidence of gallstone formation by approximately 40–50% in the post-operative period, though effect sizes vary by study population, procedure type, and dose used.

Common side effects of UDCA include diarrhoea, nausea, and abdominal discomfort. Patients should be counselled about these possibilities before starting treatment and advised to report any suspected adverse reactions via the MHRA Yellow Card scheme (www.mhra.gov.uk/yellowcard or the Yellow Card app). Contraindications and precautions are detailed in the Summary of Product Characteristics (SmPC) for individual preparations (e.g., Ursofalk); patients and prescribers should refer to this document for full prescribing information.

Experiencing these side effects? Our pharmacists can help you navigate them →

Additional preventive strategies include:

• Regular, balanced meals: Eating at consistent intervals encourages regular gallbladder contraction, reducing bile stasis.

• Adequate hydration: Supports overall digestive health and bile flow.

• Physical activity: Regular exercise supports metabolic health and may modestly reduce gallstone risk.

Patients should be informed about the rationale for UDCA at their pre- or post-operative appointments, including its off-label status in this context, and encouraged to complete the full prescribed course if it is recommended by their bariatric team.

When to Seek Medical Advice and Long-Term Outlook

Patients should contact their GP promptly for recurrent upper abdominal pain or fatty food intolerance, and call 999 for severe pain, jaundice, or fever; long-term outlook after cholecystectomy is excellent.

Knowing when to seek medical attention is an important aspect of self-management following sleeve gastrectomy. Whilst mild, transient digestive discomfort is common in the early post-operative period, certain symptoms warrant prompt assessment to rule out gallbladder complications or other serious conditions.

Contact your GP or bariatric team promptly if you experience:

• Recurrent episodes of upper right abdominal or epigastric pain, particularly after eating

• Nausea or vomiting that is new or worsening

• Intolerance to fatty foods accompanied by pain or bloating

• Any symptoms that are interfering with your ability to eat or maintain adequate nutrition

Seek urgent medical attention (call 999 or go to A&E) if you develop:

• Severe, unrelenting abdominal pain

• Severe epigastric pain radiating to the back, with vomiting (which may indicate gallstone pancreatitis)

• High fever with rigors (shaking chills)

• Jaundice (yellowing of the skin or eyes)

• Signs of sepsis, including rapid heart rate, confusion, or extreme fatigue

The long-term outlook for patients who develop gallbladder problems after gastric sleeve surgery is generally very good, particularly when the condition is identified and managed in a timely manner. Laparoscopic cholecystectomy is a safe, routine procedure with a low complication rate, and the vast majority of patients recover fully and continue to benefit from the weight loss and metabolic improvements achieved through their bariatric surgery.

Ongoing bariatric follow-up is an important opportunity to monitor for gallbladder symptoms alongside nutritional status, weight trajectory, and comorbidity management. The British Obesity and Metabolic Surgery Society (BOMSS) recommends a minimum of two years of specialist follow-up after bariatric surgery, with ongoing annual monitoring in primary care thereafter, in line with local shared-care pathways. Actual follow-up arrangements vary between NHS trusts, and patients should clarify the schedule with their bariatric team. Patients are encouraged to maintain open communication with their bariatric team and not to dismiss new abdominal symptoms as simply part of their post-operative adjustment.

Key references: NICE CG188: Gallstone disease — diagnosis and management; NICE CKS: Gallstones; NHS website: Gallstones; BOMSS guidance on follow-up of bariatric surgery patients and medications after bariatric surgery; MHRA/EMC SmPC for ursodeoxycholic acid (e.g., Ursofalk); AUGIS Pathway for the Management of Acute Gallstone Disease.

Frequently Asked Questions